Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
AVVantgarde Bio is a gene therapy startup that has developed two adeno-associated viral (AAV)-based platforms with increased transfer capabilities to enable the delivery of large genes. Gene therapy based on AAV vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company’s two AAV-based […]
Kuano is aiming to transform the discovery of enzyme inhibitor drugs using a platform that combines quantum transition state simulation and AI led chemistry. Enzyme catalysis occurs via thermodynamically favoured quantum transition states, which represent an attractive conformation for targeting enzyme inhibitors. Kuano’s proprietary in silico approach rapidly simulates the quantum transition state and generates […]
Nuevocor is a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies. The company’s lead programme is an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. The company also plans to address other untreatable cardiomyopathies using their novel target discovery platform. […]